Tafinlar — Competitive Intelligence Brief

Tafinlar (dabrafenib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor. Area: Oncology.

marketed Kinase Inhibitor Serine/threonine-protein kinase B-raf Oncology

Target snapshot

Tafinlar (dabrafenib) — Novartis. Tafinlar blocks the activity of a mutated protein called BRAF that is involved in cancer cell growth.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tafinlar TARGET	dabrafenib	Novartis	marketed	Kinase Inhibitor	Serine/threonine-protein kinase B-raf	2013-01-01
Zelboraf	vemurafenib	Hoffmann La Roche	marketed	Kinase Inhibitor [EPC]	Serine/threonine-protein kinase B-raf	2011-01-01
Romvimza	VIMSELTINIB	Deciphera Pharms	marketed	Kinase Inhibitor [EPC]		2025-01-01
Itovebi	INAVOLISIB	Genentech Inc	marketed	Kinase Inhibitor [EPC]		2025-01-01
Hernexeos	ZONGERTINIB	Boehringer Ingelheim	marketed	Kinase Inhibitor [EPC]		2025-01-01
Wayrilz	RILZABRUTINIB	Genzyme Corp	marketed	Kinase Inhibitor [EPC]		2025-01-01
Itovebi	inavolisib	Pfizer	marketed	Kinase Inhibitor [EPC]	phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)	2024-01-01

Recent regulatory actions (last 90 days)

• 2026-02-26 — Hernexeos · FDA · approved · US · Boehringer Ingelheim

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase Inhibitor class)

1. Novartis · 5 drugs in this class
2. Pfizer · 3 drugs in this class
3. Bayer · 2 drugs in this class
4. Boehringer Ingelheim · 2 drugs in this class
5. Hoffmann-La Roche · 1 drug in this class
6. Exelixis Inc · 1 drug in this class
7. Novartis Pharm · 1 drug in this class
8. Osi Pharms · 1 drug in this class
9. Exelixis · 1 drug in this class
10. Roche · 1 drug in this class